Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond B Nagle

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Cancer Research|July 25, 2019
Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate CancerCynthia S Rubenstein, Jaime M C Gard, Mengdie Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerSetsuko K Chambers, Mary C Clouser, Amanda F Baker, et al.
The Prostate|August 14, 2012
Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancerAmit M Algotar, M Suzanne Stratton, Frederick R Ahmann, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Cancer Research|July 25, 2019
Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate CancerCynthia S Rubenstein, Jaime M C Gard, Mengdie Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerSetsuko K Chambers, Mary C Clouser, Amanda F Baker, et al.
The Prostate|August 14, 2012
Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancerAmit M Algotar, M Suzanne Stratton, Frederick R Ahmann, et al.
Pageof 8